119 The Anti-HIV Drug Pipeline
نویسندگان
چکیده
منابع مشابه
Anti-hiv Drug Targets
ANTI-HIV DRUG TARGETS HIV is a retrovirus, with a simple structure described in Box 1, and illustrated in Figure 1. It contains genes coding for a number of unique viral enzymes, required at different stages of the virus’s life cycle (see Box 2 and Figure 2). One of these is reverse transcriptase, required to make copies of the viral genes once it has infected human cells. Another is HIV protea...
متن کاملAntimalaria Drug Development & Pipeline
Artemisin traditionally cleave the peroxide bond by Fe(II) found in heme proteins, thus generating toxic oxygen radicals. Synthetic peroxides, thus are proving to be useful substitutes for artemisinin. The first-generation ozonide OZ277, known as arterolane [1], has been found to inhibit the growth of chloroquine-resistant (K1) and chloroquine sensitive (NF54) parasite strains. In 2012, the com...
متن کامل2'-Deoxythymidine adducts from the anti-HIV drug nevirapine.
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used against HIV-1. Currently, NVP is the most widely used anti-HIV drug in developing countries, both in combination therapy and to prevent mother-to-child transmission of HIV. Despite its efficacy against HIV, NVP produces a variety of toxic responses, including hepatotoxicity and skin rash. It is also associated wit...
متن کاملToward the Development of a Single-Round Infection Assay Based on EGFP Reporting for Anti-HIV-1 Drug Discovery
Background: The rapid increase of HIV-1 strains resistant to current antiretroviral drugs is a challenge for successful AIDS therapy. This necessitates the development of novel drugs, and to this end, availability of screening systems for in vitro drug discovery is a priority. Herein, we report the modification of a previously developed system for increased sensitivity, ease of use, and cost-ef...
متن کاملNew anti-HCV agents in the pipeline
Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferona monotherapy in the early 90s’ to the approval of telaprevir and boceprevir based triple therapies with pegylated interferona and ribavirin in 2011, the chances of curing patients infected with HCV genotype 1 have improved dramatically to reach approximately 70%. Significant f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAIDS Journal of Acquired Immune Deficiency Syndromes
سال: 2014
ISSN: 1525-4135
DOI: 10.1097/01.qai.0000446699.46471.14